Equities Analysts Set Expectations for MDGL FY2028 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities researchers at Leerink Partnrs upped their FY2028 earnings estimates for shares of Madrigal Pharmaceuticals in a research report issued to clients and investors on Thursday, October 31st. Leerink Partnrs analyst T. Smith now forecasts that the biopharmaceutical company will post earnings per share of $38.76 for the year, up from their prior forecast of $38.44. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($27.27) per share.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.94) by $2.02. The business had revenue of $62.18 million for the quarter, compared to the consensus estimate of $34.60 million. During the same period in the previous year, the business posted ($5.34) EPS.

Several other brokerages have also recently weighed in on MDGL. Evercore ISI decreased their price target on Madrigal Pharmaceuticals from $405.00 to $360.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. JMP Securities increased their target price on shares of Madrigal Pharmaceuticals from $381.00 to $385.00 and gave the company a “market outperform” rating in a research report on Tuesday, July 16th. Oppenheimer reduced their price objective on shares of Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. StockNews.com raised shares of Madrigal Pharmaceuticals to a “sell” rating in a research note on Saturday, October 12th. Finally, Citigroup dropped their target price on shares of Madrigal Pharmaceuticals from $382.00 to $371.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $347.33.

Madrigal Pharmaceuticals Stock Performance

NASDAQ MDGL opened at $337.61 on Monday. The company has a market capitalization of $7.36 billion, a price-to-earnings ratio of -13.46 and a beta of -0.46. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals has a twelve month low of $133.99 and a twelve month high of $337.63. The stock has a fifty day simple moving average of $230.57 and a 200 day simple moving average of $244.46.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MDGL. Avoro Capital Advisors LLC raised its position in Madrigal Pharmaceuticals by 5.7% in the 2nd quarter. Avoro Capital Advisors LLC now owns 2,055,555 shares of the biopharmaceutical company’s stock valued at $575,884,000 after buying an additional 111,111 shares during the last quarter. Paulson & CO. Inc. lifted its position in shares of Madrigal Pharmaceuticals by 4.2% during the second quarter. Paulson & CO. Inc. now owns 1,850,000 shares of the biopharmaceutical company’s stock valued at $518,296,000 after purchasing an additional 75,000 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Madrigal Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,668,806 shares of the biopharmaceutical company’s stock worth $445,638,000 after purchasing an additional 94,064 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Madrigal Pharmaceuticals by 106.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 803,213 shares of the biopharmaceutical company’s stock worth $214,491,000 after purchasing an additional 414,484 shares during the last quarter. Finally, Fiera Capital Corp bought a new stake in Madrigal Pharmaceuticals in the 2nd quarter worth about $32,335,000. Institutional investors own 98.50% of the company’s stock.

Insider Buying and Selling

In other news, Director Richard S. Levy sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $300.94, for a total transaction of $1,504,700.00. Following the transaction, the director now directly owns 11,012 shares of the company’s stock, valued at $3,313,951.28. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Madrigal Pharmaceuticals news, Director Richard S. Levy sold 5,000 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $300.94, for a total value of $1,504,700.00. Following the transaction, the director now directly owns 11,012 shares of the company’s stock, valued at approximately $3,313,951.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO William John Sibold sold 6,363 shares of Madrigal Pharmaceuticals stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the transaction, the chief executive officer now owns 55,887 shares of the company’s stock, valued at $13,626,927.21. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 22.80% of the stock is owned by company insiders.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.